C4 Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

c4therapeutics.com

Founded Year

2016

Stage

IPO | IPO

Total Raised

$243M

Date of IPO

10/2/2020

Market Cap

0.26B

Stock Price

5.62

About C4 Therapeutics

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

C4 Therapeutics Headquarter Location

490 Arsenal Way Suite 200

Watertown, Massachusetts, 02472,

United States

617-231-0700

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing C4 Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned C4 Therapeutics in 1 CB Insights research brief, most recently on Aug 3, 2021.

Expert Collections containing C4 Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

C4 Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C4 Therapeutics Patents

C4 Therapeutics has filed 9 patents.

The 3 most popular patent topics include:

  • Proteins
  • Transcription factors
  • Cell biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/4/2020

2/22/2022

Cyclopropanes, Experimental cancer drugs, Cyclopentanes, Proteins, Monoclonal antibodies

Grant

Application Date

3/4/2020

Grant Date

2/22/2022

Title

Related Topics

Cyclopropanes, Experimental cancer drugs, Cyclopentanes, Proteins, Monoclonal antibodies

Status

Grant

Latest C4 Therapeutics News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of C4 Therapeutics, Inc. - CCCC

Apr 28, 2022

On April 8, 2022, the Company issued a press release entitled “C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader”. The press release disclosed, among other data, that of the “[f]our patients [who] received single agent CFT7455 at the starting dose of 50 μg per day”, “[t]wo of these patients  were dose reduced to 25 μg per day due to neutropenia, a known on-target toxicity associated with IKZF1/3 degraders” and that “[t]wo dose-limiting toxicities (DLTs) were observed at the 50 μg per day starting dose, both consistent with on-target activity[. ]”  On this news, C4’s stock price fell $3.31 per share, or 29.24%, to close at $8.01 per share on April 11, 2022. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com . CONTACT:

C4 Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

C4 Therapeutics Rank

  • When was C4 Therapeutics founded?

    C4 Therapeutics was founded in 2016.

  • Where is C4 Therapeutics's headquarters?

    C4 Therapeutics's headquarters is located at 490 Arsenal Way, Watertown.

  • What is C4 Therapeutics's latest funding round?

    C4 Therapeutics's latest funding round is IPO.

  • How much did C4 Therapeutics raise?

    C4 Therapeutics raised a total of $243M.

  • Who are the investors of C4 Therapeutics?

    Investors of C4 Therapeutics include Cobro Ventures, Perceptive Advisors, RTW Investments, RA Capital Management, Nextech Invest and 22 more.

  • Who are C4 Therapeutics's competitors?

    Competitors of C4 Therapeutics include Pin Therapeutics and 1 more.

You May Also Like

Amphista Therapeutics Logo
Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins.

P
Pin Therapeutics

Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Kymera Therapeutics Logo
Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.